Related Experiment Videos
Rationale for targeting interleukin-17 in the lungs
1Lung Pharmacology Group, Department of Allergology and Respiratory Medicine, Institute of Internal Medicine, Göteborg University, Guldhedsgatan 10A, SE-41346 Gothenburg, Sweden. anders.linden@lungail.gu.se
Current Opinion in Investigational Drugs (London, England : 2000)
|February 5, 2004
Summary
Targeting interleukin-17 (IL-17) may offer new treatments for lung diseases. Blocking IL-17 could normalize neutrophil activity, improving patient outcomes in conditions like severe asthma.
Area of Science:
- Pulmonary immunology
- Inflammatory lung diseases
Background:
- Exaggerated neutrophil accumulation in airways is linked to clinical decline in lung diseases such as severe asthma.
- Current pharmacotherapies do not effectively manage this exaggerated neutrophil activity.
Purpose of the Study:
- To review the scientific rationale for targeting interleukin-17 (IL-17) in inflammatory lung diseases.
- To explore IL-17's role in regulating neutrophil activity in the lungs.
Main Methods:
- Literature review of existing evidence on IL-17 and neutrophil function in lung inflammation.
- Analysis of the role of IL-17 in orchestrating neutrophil activity.
Main Results:
- Evidence indicates that IL-17 production and release are central to orchestrating neutrophil activity in the lungs.
- IL-17 plays a key role in the inflammatory processes of various lung diseases.
Conclusions:
- Local blockade of IL-17 is a hypothetical therapeutic strategy to normalize exaggerated neutrophil activity.
- Targeting IL-17 presents a promising avenue for developing novel pharmacotherapies for inflammatory lung diseases.